Trump Takes Aim at High Drug Prices With New Executive Order
Trump Signs Executive Order to Lower Drug Prices
President Donald Trump took action to address sky-high prescription drug prices in the United States, signing an Executive Order designed to bring costs down for American patients and taxpayers. The order aims to tackle the issue of foreign countries benefiting from lower drug prices while American consumers shoulder the burden of inflated costs.
Targeting International Pricing Practices
The Executive Order instructs the U.S. Trade Representative and the Secretary of Commerce to investigate and address practices by foreign nations that might be intentionally undercutting drug prices in the U.S. market, contributing to higher prices for American consumers.
Seeking ‘Most-Favored-Nation’ Pricing
The Secretary of Health and Human Services has been tasked with creating a system allowing American patients to purchase drugs directly from manufacturers at the lowest prices offered to other nations. This ‘Most-Favored-Nation’ pricing would bypass middlemen and potentially lead to significant savings for patients.
If drug manufacturers refuse to offer these discounted prices, the Order empowers the Secretary of Health and Human Services to propose regulations mandating ‘Most-Favored-Nation’ pricing and implement other measures to curb drug costs and unfair competition.
Highlighting the Price Disparity
The White House emphasized the stark contrast in drug prices between the U.S. and other developed nations. Americans often pay significantly more for brand-name drugs compared to citizens of other OECD countries, even after factoring in manufacturer discounts. The U.S., despite having a relatively small share of the world’s population, contributes a disproportionate amount to global pharmaceutical profits.
The administration argues that drug manufacturers leverage discounts offered in foreign markets to gain access to those countries, then compensate for those lower prices by charging Americans higher prices. This, they claim, results in American taxpayers and patients subsidizing both drug manufacturer profits and healthcare systems in other nations.
Pushing Back Against Biden Administration Actions
The White House also took a jab at the Biden Administration’s drug pricing negotiations, stating that they resulted in prices that were, on average, 78 percent higher than those negotiated in 11 comparable countries.
The Trump administration contrasted this with their own efforts, particularly their initiative to prevent Medicare beneficiaries from paying more for drugs than citizens of economically similar countries, a move they claim the Biden Administration rescinded.
Prioritizing American Patients
President Trump framed the Executive Order as part of his ongoing commitment to putting American patients first and securing a fairer deal for consumers when it comes to prescription drug costs.
